The treatment of multiple myeloma (MM) has entered the era of immunotherapy. In particular, the emergence of Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with relapsed/refractory multiple myeloma (R/R MM). However, challenges such as resistance caused by antigen loss, prolonged manufacturing cycles (vein-to-vein time), and potential severe toxicities remain major hurdles in clinical practice. At a recent academic conference, Professor Yi Lin, the Jess S. Jackson Family Professor of Cancer Research at Mayo Clinic, shared in-depth insights on the theme "CAR-T Cell Manufacturing: Scientific Progress and Technological Innovation." This article aims to extract the core academic viewpoints from Professor Yi Lin's report and explore how iterations in CAR-T manufacturing processes translate into clinical benefits.

In June 2026 local time, the European Hematology Association (EHA) Annual Congress was grandly held. In the Multiple Myeloma (MM) session, top global hematology experts engaged in in-depth dialogues regarding the treatment pathways for newly diagnosed multiple myeloma (NDMM), liquid biopsy for prognostic assessment, and intensified treatment regimens for ultra-high risk patients. This session was chaired by Professor Pieter Sonneveld from the Erasmus University Medical Center (Erasmus MC) in the Netherlands. It covered core topics such as the value of autologous stem cell transplantation (ASCT) in the era of quadruplet regimens, the clinical application of circulating tumor cells (CTC), and precision strikes for ultra-high risk patients.

In the era of rapidly evolving immunotherapy, determining the optimal bridging strategy to hematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge. At EHA 2026, Prof. Meng Lü and colleagues from Peking University People's Hospital presented an important oral study based on a large patient cohort, comparing the efficacy of CAR-T therapy and antibody-based immunotherapy as bridging treatments before transplantation and identifying key factors influencing post-transplant outcomes.

As targeted therapies continue to transform the treatment landscape of chronic lymphocytic leukemia (CLL), therapeutic goals are evolving beyond long-term disease control toward deeper remissions, fixed-duration treatment strategies, and even the possibility of functional cure. At EHA 2026, several landmark studies provided important evidence supporting this paradigm shift.

Treatment options remain extremely limited for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who relapse after CD7 CAR-T therapy. Although previous studies of humanized CD5 CAR-T cells demonstrated encouraging antitumor activity, long-term follow-up revealed a significant safety challenge: a high incidence of severe and sometimes fatal infections.

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal subtype of DLBCL characterized by unique clinicopathological features and an increased risk of central nervous system (CNS) relapse. Due to its low incidence, comprehensive investigations into its biological characteristics have remained limited.

Complement C5 inhibitors have transformed the management of paroxysmal nocturnal hemoglobinuria (PNH) and remain the current standard first-line therapy. However, despite effective control of intravascular hemolysis, many patients continue to experience persistent anemia, limited hemoglobin recovery, and clinically significant extravascular hemolysis, leaving substantial unmet medical needs.

At the highly anticipated Plenary Session of the 2026 European Hematology Association (EHA) Congress, Professor Yizhen Li from the Children's Hospital of Soochow University presented his team’s original research findings.